Langendorff-perfused rat hearts treated with EPO exhibited significantly improved postischemic recovery of left ventricular developed pressure (LVDP) and reduced infarct size compared with control hearts. Perfusion with the mitogen/extracellular signal-regulated kinase (MEK) inhibitor U0126 just before and concomitant with EPO treatment abolished EPO-induced phosphorylation of the MEK substrate extracellular signal-regulated kinase (ERK) but had no effect of EPOmediated cardioprotection. EPO treatment of the perfused hearts induced translocation of protein kinase C (PKC) ε isoform to the membrane fraction of the hearts and the protective effect of EPO was significantly inhibited by the PKC catalytic inhibitor chelerythrine added before and concomitant with EPO. These data demonstrate that EPO-mediated activation of the PKC signaling pathway before or during ischemia is required for the cardioprotective effect of EPO during ischemia-reperfusion injury. Perfusion with the phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 or wortmannin just before and concomitant with EPO treatment attenuated EPO-induced phosphorylation of the PI3K substrate Akt but had no effect on EPO-mediated cardioprotection. However, when wortmannin was added during EPO treatment and continued during reperfusion, EPO-mediated cardioprotection was significantly inhibited. We also show that postischemia EPO treatment at the onset of reperfusion significantly improved recovery of LVDP and reduced infarct size. Postischemia cardioprotection by EPO required the PI3K pathway but was not affected by inhibition of PKC at the time of EPO treatment.
type I superfamily of single-transmembrane cytokine receptors. The ability of EPO to stimulate the production of red blood cells has led to the use of the recombinant form of human EPO in clinical practice to prevent or treat anemia that is associated with various medical conditions, including cancer, surgery, and renal failure. In a series of preclinical studies investigating effects of EPO in nonhematopoietic tissues, recombinant EPO administration has been shown to exert a major tissue-protective effect in experimental models of ischemic injury involving neurons, retina, and the kidney (1) (2) (3) . Furthermore, recombinant EPO was found to exhibit significant therapeutic value in rodent models of diabetic neuropathy (4), autoimmune encephalomyelitis (5) , and stroke (6) . In a clinical study, recombinant EPO has been shown to be beneficial and safe when administered to patients with acute stroke (7) .
Studies in our laboratory, as well as others, have shown that EPO also protects cardiac myocytes against ischemic injury in a number of different model systems (8) (9) (10) (11) (12) (13) (14) (15) (16) . In previous work, we described the expression of EPOR in cardiac myocytes and showed that recombinant EPO exerts a rapid and dose-dependent cardioprotective effect when administered directly to the isolated, Langendorff-perfused rat heart immediately before ischemia-reperfusion injury (17) . This previous work also demonstrated the ability of EPO to preserve ATP levels in the ischemic myocardium. The short time period of EPO treatment suggested that EPO-mediated protection occurred through a rapid mechanism, such as posttranslational modification of second messengers, rather than through mechanisms that required initiation of gene transcription and new protein synthesis.
EPO-mediated activation of Akt has been implicated in the EPO-induced reduction in hypoxiainduced apoptosis in neonatal cardiac myocytes and H9c2 cells (11, 12) as well as the EPOmediated improvement in postischemic function in an isolated, perfused rat heart model (13) , while another study has suggested that EPO-mediated cardioprotection may occur through activation of ERK signaling (18) . In the present study, we investigated the mechanism of the acute cardioprotective effect of EPO in the isolated, Langendorff-perfused heart model focusing on specific signaling pathways, including the phosphatidylinositol-3-kinase (PI3K)/Akt, mitogen/extracellular signal-regulated kinase (MEK)/extracellular signal-regulated kinase (ERK), and protein kinase C (PKC) pathways. We found that direct and brief EPO treatment of the isolated, perfused heart mediates increased phosphorylation of Akt and ERK1/2 as well as the translocation of the PKCε isoform to the membrane fraction. Using pharmacologic inhibitors of specific signaling pathways, we have shown that the rapid cardioprotective effect of EPO during ischemia-reperfusion injury requires the PKC pathway before the onset of ischemia and the PI3K pathway during reperfusion.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats weighing ~300 g were used in this study. All animals received humane care in accordance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH publication No. 85-13, revised 1996) . The animals were maintained in standard housing conditions with dry diet and water available ad libitum.
Reagents
Recombinant human EPO (Procrit, Ortho Biotech, Bridgewater, NJ) was purchased from the outpatient pharmacy at Duke University Medical Center. Rabbit polyclonal anti-phospho-ERK (Thr 202/Thr 204), total ERK, anti-phospho-Akt (Ser 473), and anti total-Akt antibodies were from Cell Signaling Technologies (Beverly, MA). The monoclonal antibody for PKCε was obtained from Transduction Laboratories (Lexington, KY) and the polyclonal antibody for PKCδ was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The kinase inhibitors LY294002, wortmannin, and chelerythrine were purchased from Calbiochem (San Diego, CA) and U0126 was purchased from Promega (Madison, WI). The inhibitors were reconstituted freshly in DMSO before use and protected from light exposure during the experiments.
Isolated perfused heart preparation
Rats were anesthetized with an i.p. injection of pentobarbital sodium (25 mg/kg of body weight) followed by administration of 100 U of i.v. heparin sodium. The heart was excised and arrested in ice-cold Krebs-Henseleit (KH) buffer and connected via the aorta to the perfusion cannula. Retrograde perfusion was initiated under constant pressure of 100 cm H 2 O as described previously (19) . Hearts were perfused with non-recirculating KH buffer containing 120 mM NaCl, 4.6 mM KCl, 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 1.25 mM CaCl 2 , 25 mM NaHCO 3 , and 11 mM glucose at pH 7.4. The perfusate was equilibrated with 95% O 2 and 5% CO 2 and maintained at a temperature of 37°C.
Left ventricular developed pressure
To monitor contractility, a fluid-filled latex balloon was inserted into the left ventricle. The balloon was connected to a Statham pressure transducer and inflated to achieve an end-diastolic pressure of 5-10 cm H 2 O. Global no-flow ischemia was imposed by cross-clamping the perfusate inflow line while the hearts were immersed in perfusate at 37°C. At the end of the ischemic period, the balloon was collapsed during the first 5 min of reperfusion to reduce the "no reflow" phenomenon (20) . To assess recovery of contractile function, the balloon was reinflated to 5-10 cm H 2 O after 5 min of reperfusion. A Maclab/2e and Chart v4.2.2 software (AD Instruments; Colorado Springs, CO) were used to collect and process hemodynamic parameters.
Experimental protocols
The design of the experiments to assess functional recovery is illustrated in Fig. 1 . All isolated hearts were stabilized for 25 min during perfusion of KH buffer followed by 20 min of global normothermic ischemia, and 40 min of reperfusion with KH buffer. EPO treatment consisted of perfusion of the hearts with 150 ml of KH buffer containing 10 U/ml of EPO administered over ~12 min with typical flow rates of 10-14 ml/min. This concentration of EPO is comparable to levels used in experiments involving direct stimulation of EPO-responsive hematopoietic cells and is higher than the physiologic concentration in human plasma (10-26 milliunits/ml). As in previously published experiments (17) , as a control, the same volume of vehicle (Procrit buffer) was perfused (100 mM NaCl, 20 mM sodium citrate, 0.3 mM citric acid at pH 6.9, and 2.5 mg/ml human albumin) and was shown to have no effect on any hemodynamic measurements. Treatment with the kinase inhibitors U0126, wortmannin, LY294002, and chelerythrine reconstituted in DMSO vehicle was initiated 5 min before initiation of EPO treatment and continued throughout EPO administration (Fig. 1D) . As a negative control for these experiments the vehicle DMSO (no EPO) was perfused in some hearts (Fig. 1A, 1B ) and the inhibitors reconstituted in DMSO (no EPO) were perfused in other hearts (Fig. 1C) . To test the importance of PI3K activation during reperfusion, the protocol shown in Fig. 1F was used; treatment with wortmannin began 5 min before EPO addition and continued throughout both EPO addition and reperfusion. As a negative control for these experiments, hearts were perfused with wortmannin alone (without EPO) over the same time period (Fig. 1E) . In some experiments, EPO was administered postischemia during the first 10 min of the reperfusion period in the absence or presence of inhibitors (Fig. 1I, 1J ).
Infarct size
For hearts examined for infarct size, the protocols described in Fig. 1 were used, with the exception that ischemia was lengthened to 30 min, and reperfusion was extended to 2 h. At the end of 2 h of reperfusion, hearts were perfused with 60 ml of a 1% solution of 2,3,5-triphenyltetrazolium chloride (TTC) dissolved in KH buffer and then incubated in 1% TTC at 37°C for 10 min, followed by fixation in 10% formaldehyde. For each heart, three crosssectional slices through the ventricles were photographed using a digital camera. Infarct size is expressed as the percent of total heart (left ventricle + right ventricle). Five hearts of each treatment type were used for analyses, however one statistical outlier identified by the Q-test for outliers was eliminated from the postischemia EPO and EPO+chelerythrine groups.
Protein analyses and Western blotting
For analysis of ERK and Akt phosphorylation, hearts were collected 5 min after the addition of EPO. Treatment with PI3K or MEK inhibitors was initiated 5 min before EPO perfusion. Approximately 500 mg of snap-frozen ventricular tissue was used for protein extraction. Tissue was homogenized on ice using a 15 ml Wheaton homogenizer in 2 ml lysis buffer (1% Triton X-100, 10% glycerol, 150 mM NaCl, 20 mM Tris-HCL, 5 mM EDTA, leupeptin 10 µg/ml, aprotinin 10 µg/ml, PMSF 1 mM, pepstatin 1 µg/ml, Na 3 VO 4 1 mM, NaF 1 mM). After sonication with a Braun-Sonic Sonicator (2×10 s output 280), the lysates were centrifuged at 16,000g for 15 min. The concentration of soluble proteins was determined using the Bio-Rad (Hercules, CA) protein assay according to the manufacturer's protocol. The proteins were heated to 95°C for 4 min in 2× Laemmli sample buffer (Bio-Rad), separated in 4-12% Tris-glycine gels (Novex, Carlsbad, CA) by SDS-PAGE and transferred to Immobilon PVDF membrane (Millipore, Billerica, MA). The membranes were blocked with 5% nonfat milk for 1 h in TBST buffer (20 mM Tris-HCL, 137 mM NaCl, 0.1% and incubated overnight at 4°C with the primary antibodies anti-phospho-ERK or anti-phospho-Akt at dilution 1:1000 in TBST containing 5% bovine serum albumin followed by incubation with horseradish peroxidaseconjugated anti-rabbit IgG secondary antibody (1:20,000; Pierce Biotechnology, Rockford, IL). Proteins were detected using SuperSignal Enhancer (Pierce) and visualized by autoradiography. Membranes were stripped and reprobed with antibodies against total ERK or Akt.
PKC translocation
Translocation of PKC from the cytosolic to the membrane fraction was analyzed using a previously described protocol (18) . Rat hearts were perfused using the experimental protocol illustrated in Fig. 1 . After 15 min of perfusion with either no EPO treatment (Control) or 10 U/ml of EPO treatment, hearts were snap-frozen and then stored in liquid nitrogen. Frozen hearts were homogenized on liquid nitrogen and then added to 1.5 ml of a homogenization buffer consisting of 50 mM Tris-HCl (pH 7.5), 10 mM EGTA, 5 mM EDTA, 0.3% β-mercaptoethanol, 10 mM benzamidine, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 10 µg/ml peptatin A, and 50 µg/ml PMSF. Homogenates were centrifuged at 1000g for 15 min at 4°C. The resulting supernatant was centrifuged at 45,000g for 30 min at 4°C, and was considered the cytosolic fraction. The resulting pellet was resuspended in this homogenization buffer and was considered the membrane fraction. Protein concentrations were determined following the Pierce BCA kit manufacturer's protocol. For analysis, 50 µg of cytosolic and membrane fractions were separated on 8% Tris-glycine gels (Invitrogen, Carlsbad, CA) and the immunoblots were incubated with antibodies against PKCε or PKCδ followed by the appropriate secondary antibodies. Protein visualization was performed using the ECL detection method per the manufacturer's protocol (Amersham Biosciences, Piscataway, NJ). Quantitation of the density of the bands was performed using NIH ImageJ software.
Statistical analysis
The data are presented as mean ± SE. Statistical analyses were performed by using StatView for Windows software version 5.0 (SAS, Cary, NC). Comparisons between two groups were performed by t test. Comparisons between multiple groups were performed by one-way ANOVA and Fisher's post hoc test. For the recovery of function data, because two different experimental protocols were used (one for preischemia EPO addition and one for postischemia EPO addition) two sets of ANOVA analyses were performed. The first was performed on all of the treatment and control groups (protocols 
RESULTS
The cardioprotective effect of EPO is not blocked by inhibition of the ERK signaling pathway
In our previous studies, we found that brief EPO treatment immediately before global ischemia was sufficient to protect Langendorff-perfused adult rat hearts against ischemia-reperfusion injury (17) . Here, we investigated the mechanisms of EPO-mediated cardioprotection focusing on signal transduction pathways that are activated in response to EPO treatment of the perfused adult heart.
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ERK activity has been implicated as a cardioprotective pathway in other models of cardiac ischemic injury (18, 21, 22) . We examined whether the cardioprotective effect of EPO is associated with EPO-mediated activation of the MEK/ERK pathway in the heart. As illustrated in Fig. 2A , treatment of the isolated, perfused heart with EPO was associated with increased phosphorylation of ERK 1 and 2. Administration of U0126, a pharmacologic inhibitor of MEK (23), inhibited constitutive and EPO-mediated ERK phosphorylation ( Fig. 2A) . To determine whether ERK activation is required for EPO-mediated cardioprotection, we treated hearts with U0126 as in the experimental protocols in Fig. 1C and 1D . Hemodynamic measurements for these hearts are summarized in Table 1 . As illustrated in Fig. 2B , brief EPO treatment immediately before ischemia resulted in significant improvement of postischemic recovery of contractile function (expressed as a percentage of preischemic LVDP; 36%±3 in control vs. 71%±3 in EPO-treated, P<0.0001). Treatment of the hearts with U0126 in the presence of EPO had no effect on EPO-mediated cardioprotection (71%±3 for EPO-treated vs. 76%±6 for EPO+U0126-treated hearts, Fig. 2B ). Compared with untreated controls, treatment with U0126 alone had a small, but significant, increase on postischemic recovery of LVDP (50%±7 in U0126-treated hearts, P<0.05); however, addition of EPO to U0126-treated hearts resulted in significantly better postischemic function than observed in U0126-treated hearts (76%±6 for EPO+U0126-treated hearts vs. 50%±7 in U0126-treated hearts, P<0.005). These results indicate that the MEK/ERK signaling pathway is not involved in the cardioprotective effect of EPO during ischemia-reperfusion injury of the isolated, perfused heart.
PKC catalytic inhibitor chelerythrine blocks EPO-mediated cardioprotection
In the next set of experiments, we investigated the role of the PKC signaling pathway in EPOmediated cardioprotection. Activation of PKC is associated with its translocation from the cytosol to the membrane (24). We investigated the ability of EPO to mediate the translocation of different PKC isoforms in the heart. Langendorff-perfused hearts were treated with EPO, and cytosolic and membrane fractions were isolated as described in Materials and Methods. Figure  3A illustrates a representative Western blot demonstrating the distribution of the ε and δ isoforms of PKC in the cytosolic and membrane fractions of hearts that were either untreated (control) or treated with EPO. EPO treatment resulted in a significant increase in the percentage of PKCε that was located in the membrane fraction (20%±7 in control vs. 48%±4 in EPO-treated hearts, P<0.05; Fig. 3B ). In contrast, the percentage of PKCδ in the cytosolic and membrane fractions remained unchanged in control and EPO-treated hearts.
Activation of PKC has previously been shown to be important in cardioprotection (25-29). To determine whether PKC activity is required for EPO-mediated cardioprotection, we administered chelerythrine, an inhibitor of the PKC catalytic site (30), to Langendorff-perfused hearts according to the experimental protocols in Fig. 1C and 1D . Hemodynamic measurements for these hearts is summarized in Table 1 . Chelerythrine treatment significantly inhibited the EPOmediated improvement in postischemic recovery of function (71%±3 for EPO-treated vs. 53%±4 in chelerythrine+EPO-treated hearts, P<0.0005, Fig. 3C ). Previous studies in H9c2 myocytes have shown that addition of 22 mM glucose can also activate PKC within 2 h of treatment (31), and additionally that treatment of myocytes with high glucose for at least 48 h can protect myocytes from hypoxic injury (31, 32). If the short-term elevation in glucose used in our heart perfusion buffer (11 mM) was activating PKC, we would expect some protection in control which would be blocked by the addition of chelerythrhine. However, addition of chelerythrine increased, rather than decreased, protection (36%±3 in control vs. 50%±5 in chelerythrinetreated hearts, P<0.01), demonstrating that any glucose-induced PKC activity is not playing a significant role in cardioprotection in this model. However, in the presence of chelerythrine, EPO treatment did not improve recovery of LVDP (53%±4 for EPO+chelerythrine-treated vs. 50%±5 for chelerythrine-treated hearts). Thus, we conclude that the rapid cardioprotective effect of EPO is mediated, at least in part, by the activation of the PKCε signaling pathway before or during ischemia.
Inhibitors of the PI3K signaling pathway block EPO-mediated cardioprotection, with critical time dependence
We also explored the ability of EPO to mediate the phosphorylation of protein kinase B/Akt, a downstream target for PI3K. In the heart, activation of the PI3K/Akt pathway by several ligandreceptor systems, including insulin-like growth factor and gp130 signaling, has been shown to be cardioprotective during ischemia-reperfusion injury (33, 34). Furthermore, PI3K/Akt activation has been associated with the cardioprotective effect of ischemic preconditioning, which protects the myocardium from injury produced by subsequent sustained ischemia (19, 35) . Thus, we hypothesized that the cardioprotective effect of EPO may be associated with EPO-mediated activation of the PI3K/Akt pathway in the heart. We therefore initially examined whether addition of PI3K inhibitors before and concomitant with EPO would block the protection afforded by EPO.
Lysates of Langendorff-perfused adult rat hearts were used to examine the effect of EPO on the phosphorylation of Akt. As illustrated in Fig. 4A , we found increased phosphorylation of Akt following brief treatment of the perfused heart with EPO. Treatment of the hearts with the PI3K inhibitors LY294002 (36), at 10 µM, or wortmannin (37), at 100 nM, blocked the EPO-induced increase in Akt phosphorylation (Fig. 4A) . To assess the importance of the PI3K/Akt pathway in EPO-mediated cardioprotection, Langendorff-perfused rat hearts were treated with EPO either in the presence or absence of the PI3K inhibitor LY294002, as illustrated in the experimental protocols in Fig. 1C and 1D . Hemodynamic measurements for these hearts are summarized in Table 1 . Treatment of the hearts with LY294002 alone had no significant effect on the recovery of cardiac function, and LY294002 treatment did not inhibit the cardioprotective effect of EPO (42%±5 in LY294002-treated vs. 75%±6 in LY294002+EPO-treated hearts, P<0.0001; Fig. 4B ). Wortmannin treatment (100 nM) also did not inhibit the cardioprotective effect of EPO when administered only before ischemia (data not shown).
However, a recent report has shown that when wortmannin is present before ischemia and during reperfusion, the cardioprotective effect of EPO pretreatment is eliminated (13) . We therefore tested whether addition of 100 nM wortmannin concurrently with EPO as well as during reperfusion, as shown in Fig. 1F , would inhibit EPO-mediated cardioprotection. Using this experimental protocol, wortmannin alone had no significant effect on recovery of LVDP (45%±5 in wortmannin-treated vs. 36%±3 in control-treated hearts; Fig. 5 ). However, addition of wortmannin concurrently with EPO as well as during reperfusion significantly inhibited EPOmediated improvement in postischemic recovery of LVDP (71%±3 in EPO-treated vs. 51%±5 in EPO+wortmannin-treated hearts, P<0.001).
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Cardioprotection afforded by postischemia treatment with EPO is blocked by LY294002 but not chelerythrine
We further investigated whether postischemia EPO treatment immediately upon reperfusion is capable of generating a cardioprotective effect comparable to the effect of EPO administered before global ischemia. Isolated, perfused hearts were either untreated or treated with EPO on reperfusion, following global ischemia in accordance with the experimental protocols illustrated in Fig. 1G and 1I . Hemodynamic measurements for these hearts is summarized in Table 2 . The results of these experiments are shown in Fig. 6 . EPO treatment upon reperfusion resulted in significant improvement of LVDP recovery (45%±4 in control hearts vs. 61%±1 in EPO-treated hearts, P<0.01). Thus, postischemia EPO treatment at the onset of reperfusion was cardioprotective, but to a lesser extent compared with preischemia EPO treatment.
Since inhibition of PKC activity blocked EPO-mediated cardioprotection with EPO treatment before ischemia (Fig. 3C) , we examined whether chelerythrine would block the cardioprotection generated by postischemia EPO treatment. Treatment with 5 µM chelerythrine alone (no EPO) did not affect recovery of function (42%±4 in chelerythrine treated vs. 45%±4 in control hearts), and concomitant treatment with chelerythrine and EPO at reperfusion did not affect EPOmediated recovery of function (69%±4 in EPO+chelerythrine-treated vs. 61%±1 in EPO-treated hearts; Fig. 6 ).
Inhibition of PI3K activity both concomitant with EPO treatment (before ischemia) and continued during reperfusion blocked EPO-mediated recovery of function (protocol Fig. 1F; Fig.  5 ), while inhibition only before ischemia did not block EPO-mediated recovery of function (protocol Fig. 1D, Fig. 4B ), indicating that PI3K activity is required for EPO-mediated cardioprotection during reperfusion. Therefore, we tested the importance of the PI3K pathway in EPO-mediated recovery of function when the hearts were treated with EPO at reperfusion. Addition of LY294002 alone (no EPO) during reperfusion did not affect recovery of function (47%±10 in LY294002-treated vs. 45%±4 in control hearts; Fig. 6 ). However, concomitant treatment of LY294002 with EPO at reperfusion significantly inhibited recovery of function (48%±3 in EPO+LY294002-treated vs. 61%±1 in EPO-treated hearts, P<0.05). Based on these data, as well as the data presented in Fig. 4 and 5, we conclude that PI3K activity during reperfusion is critical for EPO-mediated cardioprotection.
EPO addition before ischemia or upon reperfusion reduces infarct size
In addition to examining the effects of EPO on reducing postischemic contractile dysfunction, we also examined the ability of EPO treatment to reduce infarct size caused by ischemiareperfusion injury. Isolated adult rat hearts were perfused in accordance with the protocols described in Fig. 1 , with the exception that hearts were exposed to 30 min of ischemia and 2 h of reperfusion. The additional 10 min of ischemia was necessary to examine infarct caused by ischemia, which is negligible with only 20 min of ischemic injury. Infarct size in control hearts, treated according to the protocol in Fig. 1A , was 62%±6 after 30 min of ischemic injury (Fig. 7) . Addition of EPO either before ischemia per the protocol in Fig. 1B , or upon reperfusion per the protocol in Fig. 1I , significantly reduced infarct size (42%±5 and 37%±3, respectively). We then determined the ability of PKC and PI3K inhibitors to block EPO-mediated reduction in infarct size. When added before ischemia according to the protocol in Fig. 1D , chelerythrine
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significantly blocked the EPO-mediated reduction in infarct size (56%±2, Fig. 7 ). We also found that LY294002 treatment according to the protocol in Fig. 1J significantly inhibited EPOmediated reduction of infarct size when EPO was administered during reperfusion (60%±4, Fig.  7 ).
DISCUSSION
There have been a number of recent reports documenting the cardioprotective effects of EPO. EPO has been shown to protect H9c2 myocytes, neonatal rat ventricular myocytes, and adult cardiac myocytes from anoxic injury (8, 11, 12) ; isolated, perfused hearts from ischemiareperfusion injury (9, 13, (16) (17) (18) ; and hearts in intact animals from ischemia-reperfusion injury associated with coronary artery ligation (8, 10, 12, 14, 15) . Our experiments have used Langendorff-perfused, adult rat hearts to investigate the effects of direct, acute EPO treatment on cardioprotection. Using the isolated, perfused heart preparation, we were able to examine the effects of kinase inhibitors, which is difficult in intact animal studies; examine the effects of EPO directly on the heart, without the complication of EPO-mediated effects on other organ systems; and examine the effects of EPO on the function of an intact organ.
The mechanisms responsible for the protection elicited by EPO have not been completely established. EPO treatment of the heart has been shown to activate a number of signaling pathways, including STAT3, JAK1, Akt, ERK, PKC, and p38 MAPK (13, 14, 18) . In H9c2 cells, inhibition of PI3K (500 nM wortmannin), but not inhibition of the ERK pathway (PD98059), blocked the EPO-induced reduction in cell death measured after 12 h of anoxia (12) . In an adult isolated, perfused heart model, EPO addition 15 min before ischemia improved postischemic contractile function, and this protection was blocked when 1 µM wortmannin was administered concomitant with EPO before ischemia and continued during reperfusion (13) . In an infant rabbit perfused heart model, the protection observed after administration of EPO for 15 min before ischemia was blocked if EPO was coadministered with inhibitors of p38 MAPK (SB203580), ERK (PD98059), or PKC (chelerythrine) (18) . As neonates and infants have different susceptibility to hypoxia and ischemia, it is possible that the signaling pathways activated in infants could differ from those in adults.
We therefore investigated the role of potential EPO signaling pathways in adult perfused rat hearts. Consistent with these previous studies, we found that acute addition of EPO activated Akt, ERK and caused translocation of PKCε. In contrast to the results of a previous study using infant rabbit hearts that found that PKC was only one of several signaling pathways that was important for EPO-mediated cardioprotection (18), we found that before ischemia, only activation of PKC was required for cardioprotection in the adult rat heart, as assessed by either recovery of function or infarct size. The role of PKC in EPO-induced cardioprotection is consistent with a growing body of recent experimental evidence suggesting that PKCε protects the heart against ischemic injury (26, (38) (39) (40) (41) . In this study, we show that chelerythrine, a catalytic inhibitor of all PKC isoforms, inhibits EPO-mediated cardioprotection. We also found that EPO treatment of the heart led to translocation of PKCε, but not PKCδ, consistent with the possibility that PKCε is the isoform that mediates the cardioprotective effect of EPO. PKCε has been shown to produce its cardioprotective effect through action on the mitochondria. Activation of PKCε by ischemic preconditioning has been shown to elicit a cardioprotective effect by opening mitochondrial K-ATP channels (41) that have been previously shown to be important in other models of cardioprotection (42, 43) . A recent study using perfused rabbit hearts has shown that inhibition of the mitochondrial K-ATP channel can prevent EPO-mediated cardioprotection (18) .
Previous work in other laboratories has suggested a role for the PI3K pathway in EPO-mediated cardioprotection (11) (12) (13) . We found that addition of PI3K inhibitors before ischemia (protocol Fig. 1D; Fig. 4B ) did not block the protection afforded by EPO. Interestingly, Cai and Semenza, using an adult perfused rat heart model similar to the model used in this study, reported that EPO addition 15 min before ischemia improved postischemic contractile function and this protection was blocked when 1 µM wortmannin was administered concomitant with EPO, before ischemia, and continued during reperfusion (13) . We therefore examined whether addition of wortmannin before ischemia and during reperfusion would block the protection afforded by EPO. Addition of wortmannin using a protocol similar to that used by Cai and Semenza (protocol Fig. 1F ) demonstrated that inhibition of PI3K activity both before ischemia as well as during reperfusion blocked the EPO-mediated cardioprotection (Fig. 5) , suggesting that activation of the PI3K/Akt pathway on reperfusion is important for the cardioprotection. This finding is similar to studies showing that the cardioprotective effects of ischemic preconditioning can be blocked by addition of the PI3K inhibitor LY294002 at the start of reperfusion (44) . Furthermore, the data demonstrating that inhibition of PI3K activity blocks the EPO-mediated cardioprotection afforded by EPO treatment at reperfusion, as measured by both recovery of function (Fig. 6 ) and infarct size (Fig. 7) , also emphasize a critical role for PI3K activity during reperfusion in the cardioprotective effects of EPO.
Taken together, the present studies demonstrate that acute EPO treatment activates several signaling pathways in the heart, including the MEK/ERK, PI3K/Akt, and PKC pathways, but that before ischemia, only activation of the PKC pathway is required for cardioprotection. The data also indicate that during reperfusion, activation of the PI3K/Akt pathway is also important for EPO-mediated cardioprotection, regardless of whether EPO is given before or following ischemia. Future studies will investigate EPO receptor structure-function relationships in the heart and the identification of receptor domains required for EPO-mediated activation of intracellular signaling and cardioprotection. Recent preclinical studies have shown that EPO administration following cardiac ischemia significantly decreases infarct size in rabbit and rat coronary artery ligation models of myocardial infarction (14, 15) . The excellent clinical safety profile of recombinant human EPO and its cardioprotective effect during ischemia-reperfusion injury suggests that EPO may have therapeutic value in the treatment of patients with acute coronary syndromes.
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This work was supported by research grants from the National Institutes of Health (NIDDK) R21 DK-065065 (M.O.A.) and the National Heart, Lung, and Blood Institute HL-39752 (C.S. 1 . Experimental design. The isolated, Langendorff-perfused hearts were stabilized and subjected to 20 min of normothermic global ischemia followed by 40 min of reperfusion. A) Control hearts were perfused with DMSO vehicle for 15 min before ischemia. The vehicle for EPO (Procrit buffer) was previously found to have no effect on recovery (17) . B) EPO-treated hearts were perfused with DMSO beginning 5 min before EPO addition. C) Control hearts were treated with inhibitor alone, including 10 µM LY294002 (LY), 10 µM U0126, or 5 µM chelerythrine (chel). D) In hearts pretreated with EPO and an inhibitor (LY, U0, or chel), the treatment with inhibitor was initiated 5 min before EPO administration and continued during EPO treatment. E) Control hearts were treated with wortmannin alone both before ischemia as well as upon reperfusion. F) In hearts pretreated with EPO and 100 nM wortmannin, the treatment with wortmannin was initiated 5 min before EPO administration and continued during EPO treatment and throughout reperfusion. G) Control hearts for postischemia EPO treatment were perfused with KH for 30 min before ischemia, followed by 20 min of ischemia and 40 min of reperfusion. H) Control hearts were treated with inhibitor alone (10 µM LY or 5 µM chel) at reperfusion. I) Postischemia EPO treatment was administered by replacing the buffer in the Langendorff apparatus during ischemia with KH buffer containing EPO (10 U/ml in 150 ml) so that the hearts received EPO immediately upon reperfusion, which was continued for a total of 40 min after ischemia. J) In hearts treated with EPO and an inhibitor (LY or chel), the treatment with inhibitor was concomitant with EPO treatment. Figure 1A , B, E, and F. Data represent the mean (±SE) postischemia LVDP recovery as a percentage of baseline LVDP (n=6 in EPO+wortmannin group, n=5 in wortmannin alone group).
a P < 0.01 compared with control group. b P < 0.001 compared with EPO+wortmannin group. c P < 0.0001 compared with wortmannin alone group. Figure 1 , with the exception that for these hearts ischemia was extended to 30 min and reperfusion was extended to 2 h. Infarct size is expressed as the percent of total heart (left ventricle + right ventricle) that did not stain with TTC. a P < 0.05 compared with control group. b P < 0.05 compared with EPO-treated group.
c P < 0.05 compared with post-ischemia EPO-treated group.
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